Shares of Rain Oncology Inc. (NASDAQ:RAIN – Free Report) have been assigned a consensus recommendation of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among […]